| 肺癌组织多药耐药基因蛋白表达研究 |
| |
| 引用本文： | 宿利清,付秀华,孙勤暖,郭丽萍.肺癌组织多药耐药基因蛋白表达研究[J].中华全科医学,2017,15(9):1556. |
| |
| 作者姓名： | 宿利清 付秀华 孙勤暖 郭丽萍 |
| |
| 作者单位： | 内蒙古医科大学附属医院呼吸内科, 内蒙古 呼和浩特 010050 |
| |
| 摘 要： | 目的 检测肺癌体外组织药敏及多药耐药基因蛋白表达,为临床患者治疗提供依据。 方法 选取内蒙古医科大学附属医院2008—2009年50例肺癌患者,手术切除18例,支气管镜检32例;男性36例,女性14例;平均年龄(56.8±8.5)岁。采用MTT法检测组织对顺铂(DDP)、长春瑞滨(NVB)、吉西他滨(GEM)、紫杉醇(PTX)及异环磷酰胺(IFO)的药敏情况,采用IHC法检测多药耐药相关蛋白1(MRP1)、P-糖蛋白(P-gp)、拓扑异构酶Ⅱ(TopoⅡ)表达水平。 结果 (1) MRP1、P-gp、TopoⅡ在50例肺癌(10例污染)的表达率为:72.5%(29/40)、67.5%(27/40)和50.0%(20/40)。其中在鳞癌、腺癌、小细胞肺癌(SCLC)的表达率分别为76.2%、80.0%、55.6%;80.9%、80.0%、22.2%;42.9%、60.0%、55.6%。故三者在非小细胞肺癌(NSCLC)中表达差异无统计学意义(P>0.05),仅P-gp在SCLC与NSCLC之间表达差异有统计学意义(P<0.05)。(2) MRP1的表达与DDP、GEM、NVB的耐药性均呈显著正相关(P<0.05),与PTX、IFO的耐药性差异无统计学意义(P>0.05);P-gp的表达与DDP、NVB、GEM、PTX的耐药性呈显著的正相关(P<0.05),与IFO的耐药性无显著性差异(P>0.05);TopoⅡ的表达与DDP、GEM的耐药性呈显著的正相关(P<0.05),与NVB、PTX、IFO的耐药性无显著性差异(P>0.05)。 结论 肺癌耐药是多耐药基因蛋白共同作用的结果。
|
| 关 键 词： | 肺肿瘤 耐药基因 药物敏感性 |
| 收稿时间： | 2016-07-16 |
Study of resistance-related genes protein expression in lung carcinomas tissue |
| |
| Affiliation: | Department of Respiratory Medicine, the Affiliated Hospital Respiratory Medicine of Inner Mongolia Medical College, Hohhot, Inner Mongolia 010059, China |
| |
| Abstract: | Objective Through detection drug resistance gene expression and development of drug sensitivity to provide clinical personal chemotherapy. Methods We choose 50 lung tumor patients in 2008-2009 from the affiliated hospital of Inner Mongolia medical college. Thirty-two cut off by surgery, 18 from bronchoscopy. MTT assay was employed to determine the drug sensitivity. The expression levels of drug resistance genes were detected by immunohistochemistry. Results (1) The expression rates of MRP1, P-gp, and Topo II genes in the 50 cancer tissues (but 10 tissues were contaminated) were 72. 5% (29/40), 67. 5% (27/40) and 50. 0% (20/40), respectively. The expression rate of MRP1 in the adenocarcinoma, squamous and small-cell lung cancer 76. 2%, 80%, 55. 6%, but the expression rate of P-gp and TopoⅡare 80. 9%, 80%, 22. 2% and 42. 9%, 60. 0%, 55. 6%, respectively. No significant statistical difference was observed in the expression of MRP1, P-gp, and Topo II between human adenocarcinoma and squamous cell carcinoma (P > 0. 05), but a significant statistical difference was found in P-gp expression between human adenocarcinoma or squamous carcinoma cell and small-cell lung cancer (P < 0. 05). (2) A significant positive correlation was noted between MRP1 expression and the development of resistance to cisplatin, gemcitabine and vinorelbine (P < 0. 05), but no significant correlation was observed between MRP1 expression and the development of resistance to paclitaxel and ifosfamide (P > 0. 05); A significant positive correlation was observed between P-gp expression and the development of resistance to the studied drugs, namely, cisplatin, gemcitabine, vinorelbine and paclitaxel (P < 0. 05), however, no significant correlation was found between P-gp expression and the development of resistance to ifosfamide (P > 0. 05); The positive correlation expression of TopoⅡ and the degrees of chemoresistance to the cisplatin, gemcitabine paclitaxel and iphspamide were significant, respectively (P <0. 05), but there is no significant difference in the drug tolerance of vinorelbine (P > 0. 05). Conclusion Lung cancer resistance is the role of many drug resistance gene. |
| |
| Keywords: | |
|
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载全文 |
|
